| 发明名称 |
ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS |
| 摘要 |
The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases. |
| 申请公布号 |
US2015344572(A1) |
申请公布日期 |
2015.12.03 |
| 申请号 |
US201514728253 |
申请日期 |
2015.06.02 |
| 申请人 |
INSERM (Institut National de la Sante et de la Recherche Medicale) ;Mablife |
发明人 |
Le Bouteiller Philippe;Bensussan Armand |
| 分类号 |
C07K16/28;A61K9/00;A61K39/395 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating and/or preventing neovascular eye diseases, comprising the administration of an anti-CD160 antibody to a subject in need thereof. |
| 地址 |
Paris FR |
